Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

This is what it looks like when disinformation doctors pretend to value data and science to further their true objective, ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

A former Pfizer Inc. scientist denied an allegation made by House Republicans that he conspired to delay the release of Covid ...

Unlike Drs. Adam Cifu and John Mandrola, I do not constantly boast of my "nuance" or claim to be a master of "clinical ...

Novavax Inc. (NASDAQ:NVAX) is one of the best cheap stocks with huge upside potential. On June 11, BTIG maintained a Buy ...

JOHANNESBURG (AP) — Just a week had remained before scientists in South Africa were to begin clinical trials of an HIV ...

Moderna's Spikevax receives FDA approval for use in high-risk children; Pfizer, BioNTech appeal U.K. ruling in COVID-19 ...

Three simultaneous withdrawals—from the World Health Organization, USAID and the Gavi vaccine alliance—represent a ...

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.

RSV, meningococcal, and chikungunya vaccine recommendations from the previous ACIP panel are now official policy.